Urovant Sciences Ltd., a leading biopharmaceutical company headquartered in Great Britain, focuses on developing innovative therapies for urological conditions. Founded in 2018, Urovant has quickly established itself in the healthcare industry, particularly in the field of urology, with a commitment to improving patient outcomes through advanced treatments. The company’s flagship product, vibegron, is a novel oral medication designed to treat overactive bladder, setting it apart with its unique mechanism of action. Urovant’s dedication to research and development has positioned it as a key player in the urology market, with a growing portfolio aimed at addressing unmet medical needs. With a strong operational presence in North America and Europe, Urovant Sciences continues to make significant strides in enhancing the quality of life for patients suffering from urological disorders.
We don't have data for Urovant Sciences Ltd., but we can show you information about their parent organization instead.
View parent company